

NOVO NORDISK A S
Form 6-K
February 05, 2018

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

February 2, 2018

NOVO NORDISK A/S

(Exact name of Registrant as specified in its charter)

Novo Allé

DK- 2880, Bagsvaerd

Denmark

Edgar Filing: NOVO NORDISK A S - Form 6-K

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____

Trading in Novo Nordisk shares by board members, executives and associated persons on 1 February 2018

Bagsværd, Denmark, 2 February 2018 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company's board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

As from 2004, members of Novo Nordisk's Executive Management and other members of the Senior Management Board have participated in a long-term share-based incentive programme where a proportion of the calculated shareholder value creation has been allocated to a joint pool for the participants. In 2014, six current members of Executive Management (as well as other members of senior management) participated in the programme, where shares were allocated to the joint pool and the market value of the scheme was expensed in the accounts for 2014. In accordance with the principles of the programme, the Board of Directors of Novo Nordisk A/S on 31 January 2018 evaluated that the conditions for release of the joint pool of shares have been fulfilled. Accordingly, shares in the joint pool were transferred on 1 February 2018 to the six current members of Executive Management as well as other current and former members of senior management. The reporting below reflects the transfer of such shares to the six members of Executive Management.

As of 2007, a number of key employees below senior management level have also participated in a share-based programme with similar performance criteria as the programme for senior management. A programme was established for 2014, and a current employee-elected member of the Board of Directors and two current Executive Vice Presidents have participated in this programme. In line with the programme for senior management, the Board of Directors of Novo Nordisk A/S on 31 January 2018 evaluated that the conditions for release of the shares have been fulfilled and the shares were transferred to the participants on 1 February 2018 accordingly. The reporting below reflects the transfer of such shares to the employee-elected member of the Board of Directors and the Executive Vice Presidents.

1 Details of the person discharging managerial responsibilities/person closely associated

a) Name of the Board member/Executive/Associated Person Liselotte Hyeved

2 Reason for the notification

a) Position/status Member of the Board of Directors (employee representative)

b) Initial notification/Amendment Initial notification

3 Details of the issuer

a) Name Novo Nordisk A/S

b) LEI 549300DAQ1CVT6CXN342

4 Details of the transaction(s)

Description of the financial instrument, type of instrument, Shares
 a) Identification code Novo Nordisk B
 DK0060534915
 b) Nature of the transaction Other transaction (transfer of shares in accordance with long-term incentive programme)

c) Price(s) and volume(s) Price(s) Volume(s)
 DKK 0.00 500 shares

Aggregated information

d) - Aggregated volume 500 shares
 - Price DKK 0,00
 e) Date of the transaction 1 February 2018
 f) Place of the transaction Outside a trading venue

1 Details of the person discharging managerial responsibilities/person closely associated

a) Name of the Board member/Executive/Associated Person Inkerman Holding AS
 associated to Helge Lund

2 Reason for the notification

a) Position/status Member of the Board of
 Directors

b) Initial notification/Amendment Initial notification

3 Details of the issuer

a) Name Novo Nordisk A/S

b) LEI 549300DAQ1CVT6CXN342

4 Details of the transaction(s)

	Description of the financial instrument, type of instrument,	Shares
a)	Identification code	Novo Nordisk B DK0060534915
b)	Nature of the transaction	Purchase of shares
c)	Price(s) and volume(s)	Price(s) Volume(s) DKK 316.1415 3,000 shares

Aggregated information

d) -	Aggregated volume	3,000 shares
-	Price	DKK 316.1415
e)	Date of the transaction	1 February 2018
f)	Place of the transaction	Nasdaq Copenhagen

Page 4 of 20

1 Details of the person discharging managerial responsibilities/person closely associated

a) Name of the Board member/Executive/Associated Person Søren Thuesen Pedersen

2 Reason for the notification

a) Position/status Member of the Board of Directors (employee representative)

b) Initial notification/Amendment Initial notification

3 Details of the issuer

a) Name Novo Nordisk A/S

b) LEI 549300DAQ1CVT6CXN342

4 Details of the transaction(s)

Description of the financial instrument, type of instrument, Shares

a) Identification code Novo Nordisk B
DK0060534915

b) Nature of the transaction Purchase of shares

c) Price(s) and volume(s) Price(s) Volume(s)
DKK 314.00 75 shares

Aggregated information

d) - Aggregated volume 75 shares

- Price DKK 314.00

e) Date of the transaction 1 February 2018

f) Place of the transaction Nasdaq Copenhagen

1 Details of the person discharging managerial responsibilities/person closely associated

a) Name of the Board member/Executive/Associated Person Lars Fruergaard Jørgensen

2 Reason for the notification

a) Position/status President and CEO

b) Initial notification/Amendment Initial notification

3 Details of the issuer

a) Name Novo Nordisk A/S

b) LEI 549300DAQ1CVT6CXN342

4 Details of the transaction(s)

a) Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915				
b) Nature of the transaction	Other transaction (transfer of shares in accordance with long-term incentive programme)				
c) Price(s) and volume(s)	<table border="0"> <tr> <td style="text-align: right;">Price(s)</td> <td style="text-align: right;">Volume(s)</td> </tr> <tr> <td style="text-align: right;">DKK 0.00</td> <td style="text-align: right;">11,866 shares</td> </tr> </table>	Price(s)	Volume(s)	DKK 0.00	11,866 shares
Price(s)	Volume(s)				
DKK 0.00	11,866 shares				

Aggregated information

d) - Aggregated volume - Price	11,866 shares DKK 0.00
e) Date of the transaction	1 February 2018
f) Place of the transaction	Outside a trading venue

Page 7 of 20

1 Details of the person discharging managerial responsibilities/person closely associated

a) Name of the Board member/Executive/Associated Person Jesper Brandgaard

2 Reason for the notification

a) Position/status EVP, chief financial officer

b) Initial notification/Amendment Initial notification

3 Details of the issuer

a) Name Novo Nordisk A/S

b) LEI 549300DAQ1CVT6CXN342

4 Details of the transaction(s)

	Shares	
a) Description of the financial instrument, type of instrument,		
a) Identification code	Novo Nordisk B DK0060534915	
b) Nature of the transaction	Sale of shares	
c) Price(s) and volume(s)	Price(s)	Volume(s)
	DKK 313.95	16,054 shares

Aggregated information

d) - Aggregated volume	16,054 shares
- Price	DKK 313.95
e) Date of the transaction	1 February 2018
f) Place of the transaction	Outside a trading venue

1 Details of the person discharging managerial responsibilities/person closely associated

a) Name of the Board member/Executive/Associated Person Maziar Mike Doustdar

2 Reason for the notification

a) Position/status EVP, International Operations

b) Initial notification/Amendment Initial notification

3 Details of the issuer

a) Name Novo Nordisk A/S

b) LEI 549300DAQ1CVT6CXN342

4 Details of the transaction(s)

	Shares	
a) Description of the financial instrument, type of instrument,	Novo Nordisk B	
Identification code	DK0060534915	
	Other transaction (transfer of shares in accordance with long-term incentive programme)	
b) Nature of the transaction		
	Price(s)	Volume(s)
c) Price(s) and volume(s)	DKK 0.00	6,429 shares

Aggregated information

d) - Aggregated volume	6,429 shares
- Price	DKK 0.00
e) Date of the transaction	1 February 2018
f) Place of the transaction	Outside a trading venue

1 Details of the person discharging managerial responsibilities/person closely associated

a) Name of the Board member/Executive/Associated Person Maziar Mike Doustdar

2 Reason for the notification

a) Position/status EVP, International Operations

b) Initial notification/Amendment Initial notification

3 Details of the issuer

a) Name Novo Nordisk A/S

b) LEI 549300DAQ1CVT6CXN342

4 Details of the transaction(s)

	Shares	
a) Description of the financial instrument, type of instrument,		
a) Identification code	Novo Nordisk B DK0060534915	
b) Nature of the transaction	Sale of shares	
c) Price(s) and volume(s)	Price(s)	Volume(s)
	DKK 313.95	6,429 shares

Aggregated information

d) - Aggregated volume	6,429 shares
- Price	DKK 313.95
e) Date of the transaction	1 February 2018
f) Place of the transaction	Outside a trading venue

1 Details of the person discharging managerial responsibilities/person closely associated

a) Name of the Board member/Executive/Associated Person Lars Green

2 Reason for the notification

a) Position/status EVP, Business Services & Compliance

b) Initial notification/Amendment Initial notification

3 Details of the issuer

a) Name Novo Nordisk A/S

b) LEI 549300DAQ1CVT6CXN342

4 Details of the transaction(s)

Description of the financial instrument, type of instrument, Shares

a) Identification code Novo Nordisk B
DK0060534915

b) Nature of the transaction Other transaction (transfer of shares in accordance with long-term incentive programme)

c) Price(s) and volume(s) Price(s) Volume(s)
DKK 0.00 6,429 shares

Aggregated information

d) - Aggregated volume 6,429 shares

- Price DKK 0.00

e) Date of the transaction 1 February 2018